With big pharma on a radiopharmaceuticals buying spree, New York-based Actinium Pharmaceuticals has been pointed to as the next potential takeout target.

With the passage of the Inflation Reduction Act, many have questioned whether Medicare price negotiations will stifle small molecule innovation.

Laura Soucek, a former In Vivo Rising Leader, and her co-founder have built their biotech, Peptomyc, around a previously undruggable target. They spoke about successes and learnings as scientist-entrepreneurs at BioEurope Spring.

Advances in synthetic biology are moving biopharma closer to a world where treatments can be tailored while remaining cost-effective.

Addex Therapeutics’ Tim Dyer has seen the company through 22 years of ups and downs. He has kept the company afloat, and recently did the same by spinning out a new company.

BioBytes presents an overview of AI-related deals in Q1 2024. This is the first in a recurring series of quarterly deal updates.